Living With Long COVID: LONGCOVID-EXPERIENCE

NCT ID: NCT06118112

Last Updated: 2023-11-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

25 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-09-18

Study Completion Date

2024-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background: One in ten people infected with COVID-19 presents persistent COVID, which consists of the presence of symptoms three months after the acute manifestations of COVID-19 and their persistence for at least two months, without being explained by an alternative diagnosis. The characteristics and clinical approach to persistent COVID syndrome are fairly well known, but not what the experience of people with persistent COVID is in relation to their daily life, their work life, and their experience with the healthcare received. Objective: to understand the experience of patients with persistent COVID in relation to the disease, the health care received and re-entry into the world of work

Methods: Qualitative, descriptive, phenomenological study, based on individual interviews. The study protocol will be registered in Clinicaltrials.gov. People with persistent COVID treated at the Parc Taulí Hospital will be included. Sampling will be by convenience, purposive and snowball and the sample size will be determined by data saturation. Semi-structured individual or group interviews will be conducted and the data will be analyzed following a reflective thematic analysis (Brawn and Clarke). The preliminary report will be triangulated with some participants and with the results obtained from a scoping review carried out by the research team.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Long COVID Experience, Life

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Persons with- long-covid

Women and men diagnosed with persistent COVID according to WHO (World HEalth Organization) criteria: persistent symptoms three months after the acute manifestations of COVID-19 and lasting at least two months and cannot be explained by an alternative diagnosis.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* women and men diagnosed with persistent COVID between March '20 to the present according to WHO criteria (persistent symptoms three months after the acute manifestations of COVID-19 and lasting at least two months and cannot be explained by an alternative diagnosis).
* treated at the Parc Taulí Hospital
* from 18 to 65 years

Exclusion Criteria

-people who do not understand or can communicate in Catalan or Spanish.
Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universitat Autonoma de Barcelona

OTHER

Sponsor Role collaborator

Corporacion Parc Tauli

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Anna Selva

Co-principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anna Selva, MD, MPH, PhD

Role: PRINCIPAL_INVESTIGATOR

Parc Taulí, Hospital Universitari- I3PT

Juan Leiva, PhD

Role: STUDY_DIRECTOR

Universitat Autònoma Barcelona

Pilar Peña, MD

Role: PRINCIPAL_INVESTIGATOR

Parc Taulí, Hospital Universitari- I3PT

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Corporació Sanitària Parc Taulí

Sabadell, Barcelona, Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Pilar Peña, MD

Role: CONTACT

+34937231010 ext. 82054

Pilar Peña, MD

Role: CONTACT

+34937231010 ext. 82054

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Pilar Peña, MD, MSci

Role: primary

937231010 ext. 22313

Anna Selva, MD, MPH, PhD

Role: backup

937231010 ext. 22316

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LONGCOVID EXPERIENCE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Drug Intervention in Chronic Fatigue Syndrome
NCT00848692 COMPLETED PHASE2/PHASE3